Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Nezastomig · REGN-5678

Bispecific antibody · Immune activation, directed at prostate-specific membrane antigen (FOLH1) and CD28 · developed by REGENERON PHARMACEUTICALS

Phase 1/2 Most advanced trial
REGN Developer

What is Nezastomig?

Nezastomig is a bispecific antibody that binds CD28 on cytotoxic T-lymphocytes and prostate-specific membrane antigen (PSMA) on tumor cells. By engaging both, it aims to activate and redirect T cells to PSMA-expressing cells. It is studied in metastatic castration-resistant prostate cancer and clear cell renal cell carcinoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
REGN-5678
Drug type
Bispecific antibody
Targets
prostate-specific membrane antigen (FOLH1), CD28
Mechanism
Immune activation, directed at prostate-specific membrane antigen (FOLH1) and CD28
Therapy area
Oncology
Developer
REGENERON PHARMACEUTICALS (REGN)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
M355PGI1TG

Conditions studied

Clear Cell Renal Cell Carcinoma (ccRCC)Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Other drugs acting on FOLH1 / CD28

More from REGENERON PHARMACEUTICALS

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the REGN page.

Follow REGN, the company behind Nezastomig

See REGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

REGN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.